Clinical Trial Update: Hetrombopag for Low/Intermediate-1 Risk MDS With Thrombocytopenia [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial update for Hetrombopag in low/intermediate-1 risk myelodysplastic syndrome with thrombocytopenia is ongoing with unknown current status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Hetrombopag (hetrombopag)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: MDS | Phase 2, Phase 3 | Status: UNKNOWN